Su, Wu-Chou

Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung Cancer

Soria, J.-C., Ohe, Y., Vansteenkiste, J., Reungwetwattana, T., Chewaskulyong, B., Lee, K. H., Dechaphunkul, A., Imamura, F., Nogami, N., Kurata, T., et al. (2018) · New England Journal of Medicine

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 5,508

Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations

Sequist, L. V., Yang, J. C.-H., Yamamoto, N., O'Byrne, K., Hirsh, V., Mok, T., Geater, S. L., Orlov, S., Tsai, C.-M., Boyer, M., et al. (2013) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 3,228

AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer

Jänne, P. A., Yang, J. C.-H., Kim, D.-W., Planchard, D., Ohe, Y., Ramalingam, S. S., Ahn, M.-J., Kim, S.-W., Su, W.-C., Horn, L., et al. (2015) · New England Journal of Medicine

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 2,116

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials

Yang, J. C.-H., Wu, Y.-L., Schuler, M., Sebastian, M., Popat, S., Yamamoto, N., Zhou, C., Hu, C.-P., O'Byrne, K., Feng, J., et al. (2015) · The Lancet Oncology

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 1,574

Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial

Miller, V. A., Hirsh, V., Cadranel, J., Chen, Y.-M., Park, K., Kim, S.-W., Zhou, C., Su, W.-C., Wang, M., Sun, Y., et al. (2012) · The Lancet Oncology

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 961

Osimertinib in Pretreated T790M-Positive Advanced Non–Small-Cell Lung Cancer: AURA Study Phase II Extension Component

Yang, J. C.-H., Ahn, M.-J., Kim, D.-W., Ramalingam, S. S., Sequist, L. V., Su, W.-C., Kim, S.-W., Kim, J.-H., Planchard, D., Felip, E., et al. (2017) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 571

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

Garassino, M. C., Cho, B.-C., Kim, J.-H., Mazières, J., Vansteenkiste, J., Lena, H., Corral Jaime, J., Gray, J. E., Powderly, J., Chouaid, C., et al. (2018) · The Lancet Oncology

Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations

Cited by 568

Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib After Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients With EGFR -Mutated, MET Factor–Dysregulated Non–Small-Cell Lung Cancer

Wu, Y.-L., Zhang, L., Kim, D.-W., Liu, X., Lee, D. H., Yang, J. C.-H., Ahn, M.-J., Vansteenkiste, J. F., Su, W.-C., Felip, E., et al. (2018) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 333

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Treatment Response in Advanced Lung Adenocarcinomas with G719X/L861Q/S768I Mutations

Chiu, C.-H., Yang, C.-T., Shih, J.-Y., Huang, M.-S., Su, W.-C., Lai, R.-S., Wang, C.-C., Hsiao, S.-H., Lin, Y.-C., Ho, C.-L., et al. (2015) · Journal of Thoracic Oncology

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 241

Autocrine IL-6-induced Stat3 activation contributes to the pathogenesis of lung adenocarcinoma and malignant pleural effusion

Yeh, H.-H., Lai, W.-W., Chen, H. H. W., Liu, H.-S., & Su, W.-C. (2006) · Oncogene

Cytokine Signaling Pathways and InteractionsAngiogenesis and VEGF in Cancer

Cited by 230

Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial

Yang, J. C.-H., Camidge, D. R., Yang, C.-T., Zhou, J., Guo, R., Chiu, C.-H., Chang, G.-C., Shiah, H.-S., Chen, Y., Wang, C.-C., et al. (2020) · Journal of Thoracic Oncology

Lung Cancer Treatments and MutationsPharmacogenetics and Drug Metabolism

Cited by 165

Datopotamab Deruxtecan in Advanced or Metastatic Non–Small Cell Lung Cancer With Actionable Genomic Alterations: Results From the Phase II TROPION-Lung05 Study

Sands, J., Ahn, M.-J., Lisberg, A., Cho, B. C., Blumenschein, G., Shum, E., Pons Tostivint, E., Goto, Y., Yoh, K., Heist, R., et al. (2025) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsLung Cancer Research Studies

Cited by 130

Genetic variants associated with longer telomere length are associated with increased lung cancer risk among never‐smoking women in Asia: a report from the female lung cancer consortium in Asia

Machiela, M. J., Hsiung, C. A., Shu, X., Seow, W. J., Wang, Z., Matsuo, K., Hong, Y., Seow, A., Wu, C., Hosgood, H. D., et al. (2015) · International Journal of Cancer

Genetic Associations and EpidemiologyTelomeres, Telomerase, and Senescence

Cited by 90

Signal transducer and activator of transcription 3 activation up-regulates interleukin-6 autocrine production: a biochemical and genetic study of established cancer cell lines and clinical isolated human cancer cells

Huang, W.-L., Yeh, H.-H., Lin, C.-C., Lai, W.-W., Chang, J.-Y., Chang, W.-T., & Su, W.-C. (2010) · Molecular Cancer

Cytokine Signaling Pathways and InteractionsNF-κB Signaling Pathways

Cited by 86

Apolipoprotein E expression promotes lung adenocarcinoma proliferation and migration and as a potential survival marker in lung cancer

Su, W.-P., Chen, Y.-T., Lai, W.-W., Lin, C.-C., Yan, J.-J., & Su, W.-C. (2011) · Lung Cancer

Lung Cancer Research StudiesPleural and Pulmonary Diseases

Cited by 81

Preventing and treating brain metastases with three first-line EGFR-tyrosine kinase inhibitors in patients with EGFR mutation-positive advanced non-small cell lung cancer

Su, P.-L., Wu, Y.-L., Chang, W.-Y., Ho, C.-L., Tseng, Y.-L., Lai, W.-W., Su, W.-C., Lin, C.-C., & Yang, S.-C. (2018) · Therapeutic Advances in Medical Oncology

Lung Cancer Treatments and MutationsBrain Metastases and Treatment

Cited by 49